利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

544 条记录 (耗时 0.027 秒)

    Peptide vaccines for cancers expressing tumor-associated antigens
    32.
    发明公开
    Peptide vaccines for cancers expressing tumor-associated antigens 有权

    公开(公告)号：EP2465865A3

    公开(公告)日：2013-07-24

    申请号：EP12151719.7

    申请日：2008-02-21

    申请人： Oncotherapy Science, Inc.

    发明人： Tsunoda, Takuya ,  Ohsawa, Ryuji

    IPC分类号： C07K14/47 ,  A61K39/00 ,  A61P35/00 ,  C07K14/00 ,  C12N5/10 ,  G01N33/15 ,  G01N33/50 ,  C07K14/745

    CPC分类号： C07K14/47 ,  A61K39/0011 ,  A61K2039/55555 ,  C07K14/4748

    摘要： The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: SEQ ID NO: 19, 22, 30, 34, 344, 358, 41, 44, 46, 48, 78, 376, 379, 80, 100, 101, 110, 111, 387, 112, 394, 114, 116, 117, 121, 395, 133, 135, 137, 426, 174, 178, 186, 194, 196, 202, 210, 213, 214, 217, 223, 227, 228, 233, 254, 271, 272 or 288, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several (e.g., up to 5) amino acids are substituted, deleted, or added, provided the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with over-expression of the CDH3, EPHA4, ECT2, HIG2, INHBB, KIF20A, KNTC2, TTK and/or URLC10, e.g. cancers containing as an active ingredient one or more of these peptides. The peptides of the present invention find further utility as vaccines.

    WHSC1 AND WHSC1L1 FOR TARGET GENES OF CANCER THERAPY AND DIAGNOSIS
    36.
    发明公开
    WHSC1 AND WHSC1L1 FOR TARGET GENES OF CANCER THERAPY AND DIAGNOSIS 审中-公开
    WHSC1和WHSC1L1靶基因用于癌症治疗和诊断

    公开(公告)号：EP2531598A4

    公开(公告)日：2013-05-22

    申请号：EP11739560

    申请日：2011-02-02

    申请人： ONCOTHERAPY SCIENCE INC

    发明人： HAMAMOTO RYUJI ,  NAKAMURA YUSUKE ,  TSUNODA TAKUYA

    IPC分类号： C12N15/09 ,  A61K31/713 ,  A61P35/00 ,  C12Q1/68

    CPC分类号： C12N15/1137 ,  A61K31/713 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/53

    摘要： Objective methods for diagnosing a predisposition to developing cancer, for example, bladder cancer, breast cancer, cholangiocellular carcinoma, CML, esophageal cancer, HCC, NSCLC, SCLC, osteosarcoma, pancreatic cancer, prostate cancer, renal cell carcinoma, soft tissue tumor and lymphoma, are described herein. In one embodiment, the diagnostic method involves determining an expression level of a WHSC1 or WHSC1L1 gene. The present invention further provides methods of screening for therapeutic agents useful in the treatment of WHSC1 or WHSC1L1 associated disease, such as a cancer, e.g., bladder cancer, breast cancer, cholangiocellular carcinoma, CML, esophageal cancer, HCC, NSCLC, SCLC, osteosarcoma, pancreatic cancer, prostate cancer, renal cell carcinoma, soft tissue tumor and lymphoma. The present invention further provides methods of inhibiting the cell growth and treating or alleviating symptoms of WHSC1 or WHSC1L1 associated diseases. The present invention also features products, including double-stranded molecules and vectors encoding thereof as well as to compositions including them. Also, disclosed are methods of identifying substances for treating or/and preventing lung cancer, using as an index their effect on expression of a WHSC1 or WHSC1L1 gene, or a biological activity of a WHSC1 or WHSC1L1 polypeptide.

    HJURP PEPTIDES AND VACCINES INCLUDING THE SAME
    38.
    发明公开
    HJURP PEPTIDES AND VACCINES INCLUDING THE SAME 有权
    HJURP肽和疫苗包括相同

    公开(公告)号：EP2545171A1

    公开(公告)日：2013-01-16

    申请号：EP11753055.0

    申请日：2011-03-10

    申请人： OncoTherapy Science, Inc.

    发明人： NAKAMURA, Yusuke ,  TSUNODA, Takuya ,  OHSAWA, Ryuji ,  YOSHIMURA, Sachiko ,  WATANABE, Tomohisa

    IPC分类号： C12N15/09 ,  A61K35/00 ,  A61K38/00 ,  C07K7/06 ,  C07K16/18 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/00 ,  C12N5/10

    CPC分类号： C07K14/4748 ,  A61K35/12 ,  A61K38/00 ,  A61K39/00 ,  C07K7/06 ,  C07K16/18

    摘要： Isolated peptides derived from SEQ ID NO: 50 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The inventive peptides encompasses both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids sequences substituted, deleted, added or inserted, provided such modified versions retain the requisite cytotoxic T cell inducibility of the original sequence. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors, including, for example, AML, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophagus cancer, Diffused-type gastric cancer, liver cancer, NSCLC, lymphoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal carcinoma, SCLC, soft tissue tumor and testicular tumor.

    摘要翻译： 从SEQ ID NO：50衍生的分离的肽及其与HLA抗原结合并诱导细胞毒性T淋巴细胞（CTL）的片段，因此适用于癌症免疫治疗，更具体地说本文描述了癌症疫苗。 本发明的肽包括上述氨基酸序列及其修饰形式，其中一个，两个或几个氨基酸序列被取代，缺失，添加或插入，条件是这种修饰形式保留了原始序列的必需的细胞毒性T细胞诱导性 。 进一步提供了编码任何前述肽的核酸以及包含或掺入任何上述肽或核酸的药物剂，物质和/或组合物。 本发明的肽，核酸，药剂，物质和组合物在治疗癌症和肿瘤中具有特别的用途，所述癌症和肿瘤包括例如AML，膀胱癌，乳腺癌，宫颈癌，胆管细胞癌，CML，结肠直肠癌， 食管癌，扩散型胃癌，肝癌，NSCLC，淋巴瘤，骨肉瘤，卵巢癌，胰腺癌，前列腺癌，肾癌，SCLC，软组织肿瘤和睾丸肿瘤。

    MODIFIED MELK PEPTIDES AND VACCINES CONTAINING THE SAME
    39.
    发明公开
    MODIFIED MELK PEPTIDES AND VACCINES CONTAINING THE SAME 审中-公开
    改性MELK肽和疫苗含有它们的

    公开(公告)号：EP2528937A1

    公开(公告)日：2012-12-05

    申请号：EP11734528.0

    申请日：2011-01-24

    申请人： OncoTherapy Science, Inc.

    发明人： NAKAMURA, Yusuke ,  TSUNODA, Takuya ,  OHSAWA, Ryuji ,  YOSHIMURA, Sachiko ,  WATANABE, Tomohisa

    IPC分类号： C07K7/06 ,  A61K38/00 ,  A61P35/00

    CPC分类号： C12Y207/11025 ,  A61K39/0011 ,  A61K39/39 ,  C12N9/1205

    摘要： Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild type MELK epitope peptide and thus are suitable for use in the context of cancer immunotherapy or endometriosis immunotherapy, more particularly cancer or endometriosis vaccines are described herein. The present invention further provides peptides that include one, two, or several amino acid insertions, substitutions or additions to the aforementioned peptides or fragments, but yet retain the requisite cytotoxic T cell inducibility. Further provided are nucleic acids encoding any of these aforementioned peptides as well as pharmaceutical substances and compositions including any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical substances and compositions of this invention find particular utility in the treatment of cancers, tumors, and endometriosis.